Search

Your search keyword '"Schiller, Joan H."' showing total 904 results
Start Over Author "Schiller, Joan H."
904 results on '"Schiller, Joan H."'

103. A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis

Author

Hotton, Kirsten M., Khorsand, Masoud, Hank, Jacquelyn A., Albertini, Mark, Kim, Kyung Mann, Wilding, George, Salamat, M. Shahriar, Larson, Marilyn, Sondel, Paul, and Schiller, Joan H.

Subjects
Carcinoma, Renal cell -- Complications, Granulocyte-macrophage colony stimulating factor -- Evaluation, Interleukin-2 -- Evaluation, Thrombosis -- Risk factors, Health
Published
2000

104. Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: ECOG-ACRIN 5508

Author

Ramalingam, Suresh S., primary, Dahlberg, Suzanne E., additional, Belani, Chandra P., additional, Saltzman, Joel N., additional, Pennell, Nathan A., additional, Nambudiri, Gopakumar S., additional, McCann, John C., additional, Winegarden, Jerome D., additional, Kassem, Mohammed A., additional, Mohamed, Mohamed K., additional, Rothman, Jan M., additional, Lyss, Alan P., additional, Horn, Leora, additional, Stinchcombe, Thomas E., additional, and Schiller, Joan H., additional

Published
2019
Full Text
View/download PDF

109. Interleukin-2-induced splenic enlargement

Author

Pozniak, Myron A., Christy, Paul S., Albertini, Mark R., Duffek, Susan M., and Schiller, Joan H.

Subjects
Interleukin-2 -- Adverse and side effects, Splenomegaly -- Causes of, Health
Abstract

Background. Splenomegaly in patients with cancer raises the suspicion of tumor involvement. Splenic enlargement in the absence of splenic metastases, however, has been reported in patients treated with interleukin-2 (IL-2) immunotherapy. This study characterizes the change in spleen size that occurred in 42 patients treated with IL-2 between 1989 and 1993 for nonhematologic malignancies. Methods. Computed tomography (CT) scans before and during immunotherapy were available for review on all 42 patients and after immunotherapy on 16 of these patients. The splenic index was measured for each CT by a single reader blinded to the time course of IL-2 therapy. Results. Mean splenic index increased 64.1% from 646 [cm.sup.3] (standard deviation [SD], 387) pre-IL-2 to 1059 [cm.sup.3] (SD, 534) during therapy with IL-2 (P < 0.0001). The splenic index remained elevated at 1112 [cm.sup.3] (SD, 633) after completion of IL-2 therapy. Conclusions. Splenomegaly, temporally associated with IL-2 therapy for nonhematologic malignancies, is likely to represent a sequela of therapy and not tumor progression. Cancer 1995;75:2737-41.

Published
1995

112. Treatment of hypercalcemia of malignancy with intravenous etidronate: a controlled, multicenter study

Author

Singer, Frederick R., Ritch, Paul S., Lad, Thomas E., Ringenberg, Q. Scott, Schiller, Joan H., Recker, Robert R., and Ryzen, Elisabeth

Subjects
Etidronate disodium -- Evaluation, Etidronate disodium -- Adverse and side effects, Hypercalcemia -- Drug therapy, Cancer -- Complications, Health
Abstract

Malignant hypercalcemia is an excess of calcium in the blood that occurs in 10 to 20 percent of patients with cancer. It is caused by increased bone loss either due to destruction of the bone by metastatic cancer, or through the production of a parathyroid hormone-like protein. (Parathyroid hormone causes the release of calcium from bone.) The usual treatment is hydration (giving the patient fluids), but this is not always effective. Etidronate sodium belongs to a group of chemicals called the diphosphonates, which bind to bone and prevent its breakdown. It has been shown to be effective in lowering calcium levels in patients with malignant hypercalcemia. A total of 157 cancer patients with hypercalcemia were randomly assigned to one of two groups: one group received hydration with saline solution (43 patients), and the other received an infusion of etidronate in saline solution (114 patients). The infusions were given once a day over a two-hour period for three days. Additional hydration was given to both groups as needed to restore fluid levels. Furosemide (Lasix) was also administered, if needed, to prevent fluid overload. By the fourth day, patients in the etidronate group had significantly lower levels of calcium than those in the saline group. Furthermore, 63 percent (72 of 114) of the patients in the etidronate group responded to the treatment, whereas only 33 percent (14 of 43) of the saline group responded to hydration alone. There were few side effects of etidronate treatment; nausea and/or vomiting occurred in 8.8 percent of patients on etidronate compared with 4.5 percent of patients receiving hydration alone. Twelve percent of the etidronate-treated group experienced mild, temporary impairment of kidney function, compared with five percent of the saline group. However, hypercalcemia and dehydration can cause kidney damage, and the adverse effect of etidronate can be minimized by administering the drug slowly over long periods of time. In fact, etidronate treatment may be more effective if the duration of treatment is increased. The most effective treatment for hypercalcemia of malignancy is cancer therapy, etidronate may be useful in the short-term for lowering elevated calcium levels.(Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

114. Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer

Author

Gerber, David E., primary, Socinski, Mark A., additional, Neal, Joel W., additional, Wakelee, Heather A., additional, Shirai, Keisuke, additional, Sequist, Lecia V., additional, Rosovsky, Rachel P., additional, Lilenbaum, Rogerio C., additional, Bastos, Bruno R., additional, Huang, Chao, additional, Johnson, Melissa L., additional, Hesketh, Paul J., additional, Subramaniam, Deepa S., additional, Dietrich, Martin F., additional, Chai, Feng, additional, Wang, Yunxia, additional, Kazakin, Julia, additional, Schwartz, Brian, additional, Schiller, Joan H., additional, Brahmer, Julie R., additional, and Kelly, Ronan J., additional

Published
2018
Full Text
View/download PDF

115. Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients

Author

Smith, Thomas J., primary, Hanna, Nasser, additional, Johnson, David, additional, Baker, Sherman, additional, Biermann, William A., additional, Brahmer, Julie, additional, Ellis, Peter M., additional, Giaccone, Giuseppe, additional, Hesketh, Paul J., additional, Jaiyesimi, Ishmael, additional, Leighl, Natasha B., additional, Riely, Gregory J., additional, Schiller, Joan H., additional, Schneider, Bryan J., additional, Tashbar, Joan, additional, Temin, Sarah, additional, and Masters, Gregory, additional

Published
2017
Full Text
View/download PDF

117. Using liquid crystals to report membrane proteins captured by affinity microcontact printing from cell lysates and membrane extracts

Author

Chang-Hyun Jang, Tingey, Matthew L., Korpi, Nichole L., Wiepz, Gregory J., Schiller, Joan H., Bertics, Paul J., and Abbott, Nicholas L.

Subjects
Cell membranes -- Research, Cell membranes -- Chemical properties, Liquid crystals -- Usage, Chemistry
Abstract

A simple procedure that permits detection of transmembrane proteins from crude cell lysates and cell membrane extracts is reported. The presence of the transmembrane proteins captured by an affinity ligand is found and amplified by the use of liquid crystals (LCs) in this procedure.

Published
2005

118. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Author

Hanna, Nasser, primary, Johnson, David, additional, Temin, Sarah, additional, Baker, Sherman, additional, Brahmer, Julie, additional, Ellis, Peter M., additional, Giaccone, Giuseppe, additional, Hesketh, Paul J., additional, Jaiyesimi, Ishmael, additional, Leighl, Natasha B., additional, Riely, Gregory J., additional, Schiller, Joan H., additional, Schneider, Bryan J., additional, Smith, Thomas J., additional, Tashbar, Joan, additional, Biermann, William A., additional, and Masters, Gregory, additional

Published
2017
Full Text
View/download PDF

119. Impact of prior radiation on survival in metastatic lung cancer ECOG-ACRIN trials.

Author

Khan, Saad A., primary, Puligandla, Maneka, additional, Dahlberg, Suzanne Eleanor, additional, Masters, Gregory A., additional, Langer, Corey J., additional, Brahmer, Julie R., additional, Hanna, Nasser H., additional, Bonomi, Philip, additional, Gerber, David E., additional, Johnson, David H., additional, Schiller, Joan H., additional, and Ramalingam, Suresh S., additional

Published
2017
Full Text
View/download PDF

120. B-F1RST: Assessment of novel blood-based biomarkers in patients with first-line advanced or metastatic NSCLC receiving atezolizumab monotherapy.

Author

Kim, Edward S., primary, Socinski, Mark A., additional, Dakhil, Shaker R., additional, Mackler, Niklas J., additional, Ikhlaque, Nadeem, additional, Mekhail, Tarek, additional, Volterra, Fabio, additional, El Khoury, Christian Antoine, additional, Schiller, Joan H., additional, Tsai, Michaela L., additional, Hayek, Fadi, additional, Neidhart, Jeffrey D., additional, Hunis, Brian, additional, Hu, Sylvia, additional, Paul, Sarah M., additional, Shames, David S., additional, Phan, See-Chun, additional, Yun, Cindy, additional, and Velcheti, Vamsidhar, additional

Published
2017
Full Text
View/download PDF

122. Putting lung cancer clinical trials into perspective

Author

Dowell, Jonathan E. and Schiller, Joan H.

Subjects
Lungs -- Surgery, Lung cancer, Non-small cell -- Care and treatment -- Research, Chemotherapy -- Health aspects, Cancer -- Chemotherapy, Radiotherapy -- Health aspects, Health
Abstract

Ganti and colleagues have provided a comprehensive overview on recent presentations involving lung cancer. However, several of the points they made in the article deserve to be put in perspective, [...]

Published
2011

123. Clinician Perceptions of Care Difficulty, Quality of Life, and Symptom Reports for Lung Cancer Patients: An Analysis from ECOG E2Z02 (Symptom Outcomes and Practice Patterns; SOAPP)

Author

Hamann, Heidi A., Lee, Ju-Whei, Schiller, Joan H., Horn, Leora, Wagner, Lynne I., Chang, Victor Tsu-Shih, and Fisch, Michael J.

Subjects
Adult, Aged, 80 and over, Male, Lung Neoplasms, Attitude of Health Personnel, Middle Aged, Prognosis, Severity of Illness Index, Article, Young Adult, Physicians, Surveys and Questionnaires, Outcome Assessment, Health Care, Quality of Life, Humans, Female, Perception, Patient Care, Neoplasm Metastasis, Practice Patterns, Physicians', Aged, Follow-Up Studies
Abstract

Despite recent therapeutic advances, lung cancer is a difficult disease to manage. This study assessed clinicians' perceptions of care difficulty, quality of life (QOL), and symptom reports for their lung cancer patients compared with their patients with breast, prostate, and colon cancer.This report focused on secondary analyses from the Eastern Cooperative Oncology Group (ECOG) Symptom Outcomes and Practice Patterns (SOAPP) study (E2Z02); outcome measures included clinician ratings of 3106 solid tumor patients. Univariate analyses focused on patterns of disease-specific perceptions; multivariable analyses examined whether disease-specific differences persisted after covariate inclusion.In univariate comparisons, clinicians rated lung cancer patients as more difficult to treat than other solid tumor patients, with poorer QOL and higher symptom reports. After covariates were adjusted, the odds of clinicians perceiving lower QOL for their lung cancer patients were 3.6 times larger than for patients with other solid tumors (odds ratio = 3.6 [95% confidence interval, 2.0-6.6]; p0.0001). In addition, the odds of clinicians perceiving weight difficulties for their lung cancer patients were 3.2 times larger (odds ratio = 3.2 [95% confidence interval, 1.7-6.0]; p = 0.0004). No other outcome showed significant differences between lung versus other cancers in multivariable models.Clinicians were more pessimistic about the well-being of their lung cancer patients compared with patients with other solid tumors. Differences remained for clinician perceptions of patient QOL and weight difficulty, even after controlling for such variables as stage, performance status, and patient-reported outcomes. These continuing disparities suggest possible perception bias. More research is needed to confirm this disparity and explore the underpinnings.

Published
2013

126. Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC: Results of a randomized phase 2 study.

Author

Lee, Jong-Seok, primary, Han, Ji-Youn, additional, Ahn, Myung-Ju, additional, Oh, In-Jae, additional, Kim, HyeRyun, additional, Lee, Dae Ho, additional, Bertino, Erin Marie, additional, Viteri Ramirez, Santiago, additional, Pennell, Nathan A., additional, Wozniak, Antoinette J., additional, Schiller, Joan H., additional, Lin, Chester, additional, Keer, Harold N., additional, Azab, Mohammad, additional, Besse, Benjamin, additional, and Camidge, D. Ross, additional

Published
2016
Full Text
View/download PDF

128. E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC—Outcomes based on chemotherapy subsets.

Author

Wakelee, Heather A., primary, Dahlberg, Suzanne Eleanor, additional, Keller, Steven M., additional, Tester, William J., additional, Gandara, David R., additional, Graziano, Stephen L., additional, Adjei, Alex A., additional, Leighl, Natasha B., additional, Butts, Charles Andrew, additional, Aisner, Seena C., additional, Rothman, Jan M., additional, Patel, Jyoti D., additional, Sborov, Mark D., additional, McDermott, Raymond S., additional, Perez-Soler, Roman, additional, Traynor, Anne M., additional, Evans, Tracey L., additional, Horn, Leora, additional, Ramalingam, Suresh S., additional, and Schiller, Joan H., additional

Published
2016
Full Text
View/download PDF

129. E3508: Randomized trial of carboplatin (C), paclitaxel (P), bevacizumab (B) with or without cixutumumab (Cx) in patients (pts) with advanced non-squamous, non-small cell lung cancer (NSCLC).

Author

Argiris, Athanassios, primary, Lee, Ju-Whei, additional, Stevenson, James, additional, Sulecki, Matthew Gerard, additional, Hugec, Vladimir, additional, Choong, Nicholas W., additional, Saltzman, Joel N., additional, Song, Wei, additional, Hansen, Richard M., additional, Evans, Tracey L., additional, Ramalingam, Suresh S., additional, and Schiller, Joan H., additional

Published
2016
Full Text
View/download PDF

130. A pooled analysis of concurrent chemoradiotherapy (CCRT) for patients with stage III non-small cell lung cancer (NSCLC) who participated in U.S. cooperative group trials: Comparing the outcomes of elderly to younger patients (pts).

Author

Stinchcombe, Tom, primary, Zhang, Ying J, additional, Vokes, Everett E., additional, Schiller, Joan H., additional, Bradley, Jeffrey D., additional, Curran, Walter John, additional, Movsas, Benjamin, additional, Schild, Steven E., additional, Clamon, Gerald H., additional, Govindan, Ramaswamy, additional, Blumenschein, George R., additional, Socinski, Mark A., additional, Ready, Neal, additional, Akerley, Wallace L., additional, Cohen, Harvey Jay, additional, Pang, Herbert, additional, and Wang, Xiaofei F., additional

Published
2016
Full Text
View/download PDF

132. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)

Author

Belani, Chandra P., primary, Dahlberg, Suzanne E., additional, Rudin, Charles M., additional, Fleisher, Martin, additional, Chen, Helen X., additional, Takebe, Naoko, additional, Velasco, Mario R., additional, Tester, William J., additional, Sturtz, Keren, additional, Hann, Christine L., additional, Shanks, James C., additional, Monga, Manish, additional, Ramalingam, Suresh S., additional, and Schiller, Joan H., additional

Published
2016
Full Text
View/download PDF

135. Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer

Author

Gerber, David E., primary, Boothman, David A., additional, Fattah, Farjana J., additional, Dong, Ying, additional, Zhu, Hong, additional, Skelton, Rachel A., additional, Priddy, Laurin L., additional, Vo, Peggy, additional, Dowell, Jonathan E., additional, Sarode, Venetia, additional, Leff, Richard, additional, Meek, Claudia, additional, Xie, Yang, additional, and Schiller, Joan H., additional

Published
2015
Full Text
View/download PDF

136. The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer

Author

Keller, Steven M., Johnson, David H., Kolesar, Jill M., Marsh, Sharon, Dahlberg, Suzanne E., McLeod, Howard L., and Schiller, Joan H.

Abstract

NAD(P)H:quinone oxidoreductase 1 (NQO1), is a cytosolic flavoenzyme that catalyzes the two-electron reduction of quinones into hydroquinones. A polymorphism (NQO1*2) alters enzymatic activity of NQO1 resulting in diminished NQO1 activity. Malignancies with NQO1*2 may be resistant to radiation and chemotherapy with resulting poorer survival. NQO1 allele was evaluated in subjects enrolled in ECOG 3590, a randomized comparison of radiation (RT) vs radiation and chemotherapy with cisplatin/etoposide (RCT) in patients with completely resected stages II and IIIa NSCLC. Overall survival was estimated using the Kaplan-Meier method and compared via the log-rank test. Cox models were used to assess the impact of covariates on outcomes. Among 152 patients with assessable samples, 24 (16%) had NQO1*2. Median follow-up was 139 months. The presence of NQO1*2/*2 was associated with decreased overall survival (OS) (median in the heterozygote/wild-type group 42.3 vs. 33.5 months in the variant group, p=0.04). In a multivariable Cox model, variant NQO1 (HR=1.58, p=0.05), age

Published
2011
Full Text
View/download PDF

137. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Author

Masters, Gregory A., primary, Temin, Sarah, additional, Azzoli, Christopher G., additional, Giaccone, Giuseppe, additional, Baker, Sherman, additional, Brahmer, Julie R., additional, Ellis, Peter M., additional, Gajra, Ajeet, additional, Rackear, Nancy, additional, Schiller, Joan H., additional, Smith, Thomas J., additional, Strawn, John R., additional, Trent, David, additional, and Johnson, David H., additional

Published
2015
Full Text
View/download PDF

141. Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0).

Author

Kris, Mark G., primary, Johnson, Bruce E., additional, Kwiatkowski, David J., additional, Wistuba, Ignacio Ivan, additional, Berry, Lynne D, additional, Haura, Eric B., additional, Socinski, Mark A., additional, Ramalingam, Suresh S., additional, Glisson, Bonnie S., additional, Waqar, Saiama Naheed, additional, Otterson, Gregory Alan, additional, Schiller, Joan H., additional, Garon, Edward B., additional, Cetnar, Jeremy Paul, additional, Politi, Katerina A, additional, Brahmer, Julie R., additional, Sequist, Lecia V., additional, Lovly, Christine Marie, additional, Kugler, Kelly, additional, and Bunn, Paul A., additional

Published
2015
Full Text
View/download PDF

142. 美国临床肿瘤学会Ⅳ期非小细胞肺癌化疗的临床实践指南更新

Author

AZZOLI, Christopher G., JR, Sherman Baker, TEMIN, Sarah, PAO, William, ALIFF, Timothy, BRHMER, Julie, JOHNSON, David H., LASKIN, Janessa L., MASTERS, Gregory, MILTON, Daniel, NORDQUIST, Luke, PFISTER, David G., PIANTADOSI, Steven, SCHILLER, Joan H., SMITH, Reily, SMITH, Tomas J., STRWN, John R., TRENT, David, and GIACCONE, Giuseppe

Subjects
临床指南, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Antineoplastic Protocols, Humans, Antineoplastic Agents, Guidelines as Topic, Societies, Medical, United States, Neoplasm Staging
Abstract

本文旨在为Ⅳ期非小细胞肺癌患者的治疗提供更新版推荐。本文资料检索源自2002年以来公布的相关随机试验文献。此指南范围限于化疗与生物治疗。更新委员会对这些文献进行了总结并提供了推荐更新。162篇文献符合标准被纳入参考。本推荐基于可改善总生存期的治疗方法。仅改善无进展生存期的治疗方法推动了对毒性及生存质量的监测。对于体力状态评分为0分或1分患者的一线治疗，可推荐以铂类为基础的细胞毒性药物的两药联用。对铂类治疗有禁忌的患者，可采用非铂类细胞毒性两药联合。对于体力状态评分为2分的患者，单一细胞毒性药物即可。对于疾病进展或经过4个周期的治疗仍对治疗无反应的患者，应停止一线细胞毒性化疗。即使在6个周期后患者对治疗仍有反应，亦应停止两药细胞毒性化疗。对于伴有明确的表皮生长因子受体（epidermal growth factor receptor, EGFR）突变的患者，可推荐一线采用吉非替尼治疗；对于EGFR突变为阴性或不明确的患者，细胞毒性化疗更佳。除具有特定临床特征的患者外，可推荐贝伐单抗与卡铂-紫杉醇联用。对于通过免疫组化证实EGFR阳性的肿瘤患者，可推荐西妥昔单抗与顺铂-长春瑞滨联用。多西紫杉醇、厄洛替尼、吉非替尼或培美曲塞被推荐作为二线治疗。对于未曾接受过厄洛替尼或吉非替尼治疗的患者，可推荐厄洛替尼作为三线治疗。现有数据不足以推荐常规三线采用细胞毒性药物。已有的证据也不足以推荐常规应用分子标记物选择化疗。

Published
2010

143. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).

Author

Edelman, Martin J., Wang, Xiaofei, Hodgson, Lydia, Cheney, Richard T., Baggstrom, Maria Q., Thomas, Sachdev P., Gajra, Ajeet, Bertino, Erin, Reckamp, Karen L., Molina, Julian, Schiller, Joan H., Mitchell-Richards, Kisha, Friedman, Paula N., Ritter, Jon, Milne, Ginger, Hahn, Olwen M., Stinchcombe, Thomas E., and Vokes, Everett E.

Published
2017
Full Text
View/download PDF

148. A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC).

Author

Burris, Howard A., primary, Gordon, Michael S., additional, Gerber, David E., additional, Spigel, David R., additional, Mendelson, David S., additional, Schiller, Joan H., additional, Wang, Yulei, additional, Choi, Younjeong, additional, Kahn, Robert S., additional, Wood, Katie, additional, Maslyar, Daniel J., additional, and Infante, Jeffrey R., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results